• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

BridgeBio slashes gene therapy budget after early-phase data fall short of 'transformational' target

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Sep 11, 2024 at 11:32: AM
via BridgeBio Pharma is slashing its gene therapy budget and pulling back from the modality after seeing the results of a phase 1/2 clinical trial. CEO Neil Kumar, Ph.D., said the data “are not yet transformational,” driving BridgeBio to shift its focus to other drug candidates and ways to treat disease.

article source
 

<



Similar threads

cafead
BridgeBio contributes rare disease assets to $300M-backed GondolaBio venture
Replies
0
Views
32
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
BridgeBio Stock Makes A Bullish Move On Dwarfism Treatment Results
Replies
0
Views
30
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
BridgeBio Builds on Positive Phase III Data for Acoramidis in ATTR-CM
Replies
0
Views
119
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
BridgeBio taps VCs for $200M, fueling oncology spinout&#039;s push to surpass KRAS class
Replies
0
Views
83
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Bayer pays $310M to buy into BridgeBio heart drug
Replies
0
Views
522
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote